Why You’re Not Losing Weight on GLP-1s Anymore

Evidence-Based Explanations — and What to Do Next
By Mary Moret, FNP-C, FNP-BC

If you are taking a GLP-1 medication such as Semaglutide or Tirzepatide and your weight loss has slowed or stalled, this is usually expected physiology — not medication failure.

As a nurse practitioner specializing in hormone optimization and metabolic health, this is one of the most common conversations I have with patients.

Large clinical trials consistently show that weight loss is most rapid in the first several months and then slows as the body adapts.

In the STEP-1 trial, semaglutide 2.4 mg weekly produced an average 14.9% weight reduction over 68 weeks, with early rapid loss followed by a flattening curve.

In SURMOUNT-1, tirzepatide resulted in approximately 15–22% weight loss over 72 weeks depending on dose, again with deceleration over time.

This pattern is biologically predictable.

References:
Wilding JPH et al., NEJM 2021 (STEP-1)
Jastreboff AM et al., NEJM 2022 (SURMOUNT-1)

When body weight decreases, resting energy expenditure declines. The body becomes more metabolically efficient — a process known as adaptive thermogenesis.

Systematic reviews confirm that metabolic adaptation persists after weight loss and contributes to plateaus.

Reference:
Nunes CL et al., Obesity Reviews 2022.

This is not “metabolic damage.” It is normal human physiology.

GLP-1 medications reduce appetite. Without adequate protein intake and resistance training, lean mass may decline during weight loss.

Body composition analyses from semaglutide trials demonstrate substantial fat mass reduction, but also proportional lean mass reduction during total weight loss.

Because lean mass influences resting metabolic rate, preservation of muscle is essential for long-term success.

Reference:
STEP-1 body composition analysis, NEJM 2021.

Plateaus may occur when:

Obesity treatment guidelines emphasize individualized dosing strategies rather than automatic escalation.

GLP-1 medications improve appetite signaling and glycemic control. They do not directly correct:

Menopause is associated with increased visceral adiposity and decreased lean mass independent of aging alone.

Reference:
The North American Menopause Society (NAMS) 2022 Position Statement.

Addressing symptomatic hormonal imbalance may improve sleep, energy, strength training consistency, and overall body composition — though hormone therapy itself is not a weight-loss medication.

A common misconception is that women over 60 should never use hormone therapy.

Guidelines state that for most healthy women younger than 60 or within 10 years of menopause onset, the benefit-risk profile is generally favorable for symptom management.

However, being over 60 does not automatically exclude someone from hormone therapy. Instead:

Transdermal estrogen, for example, may be associated with lower venous thromboembolism risk compared to oral formulations in certain populations.

Long-term follow-up of the Women’s Health Initiative found no increase in all-cause mortality after typical durations of therapy (5–7 years).

References:
NAMS 2022 Hormone Therapy Position Statement
Manson JE et al., JAMA 2017 (WHI long-term mortality data)

Hormone therapy decisions should be personalized — not fear-driven.

Bioidentical describes molecular structure. Safety depends on dose, route, patient history, and monitoring.

Weight curves flatten over time. This is documented in major GLP-1 trials.

Many patients lose significant weight without hormone therapy. However, untreated severe menopausal symptoms may indirectly impair adherence to training, sleep, and recovery.

Hormone therapy treats symptoms. It does not directly treat obesity.

If weight has been stable for more than six weeks, reassessment may include:

Persistent fatigue, hair thinning, cycle changes, cold intolerance, or strength loss warrant further clinical review.

GLP-1 medications such as Semaglutide and Tirzepatide are among the most effective anti-obesity therapies available, supported by high-quality randomized controlled trials.

Long-term success requires:

Plateaus are not failure. They are the transition from rapid loss to sustainable metabolic management.